抽吸联合替罗非班对血栓患者心功能及预后的影响

Observation of Thrombus aspiration combined tirofiban on heart function and prognosis in patients with thrombosis

目的 :探讨血栓患者采用抽吸联合替罗非班治疗后的心功能及预后的影响,为临床应用提供参考。方法:选取我院收治的500例急性ST段抬高型心肌梗死患者为观察对象,随机分为观察组和对照组,观察组患者在常规PCI基础上采用血栓抽吸+替罗非班治疗,对照组进行常规PCI,比较两组患者治疗效果、术后并发症以及不良反应等。结果 :观察组中术后TIMI血流分级Ⅲ级患者228例(91.03%),高于对照组的205例(82.07%),其组间差异有统计学意义。观察组患者术后7天时左心室射血分数为60.44±6.13(%),高于对照组的52.35±5.89(%),其组间差异有统计学意义。观察组患者中30天内主要不良心脏事件11例,发生率为4.4%;对照组30天内主要不良心脏事件25例,发生率为10%。结论 :血栓抽吸+替罗非班应用于急性ST段抬高型心肌梗死介入治疗中,可明显改善术后冠状动脉的血流灌注,改善左心室射血功能,减少30天内主要不良心脏事件发生率。

Objective To evaluate the curative effect of the tirofiban in patients with acute myocardial infarction in PCI, and provide reference for clinical application. Methods 290 cases of acute myocardial infarction patients were selected as the observation object, and randomlywere divided into the observation group and control group, the patients in the observation group addedtirofibanon the basis of conventional treatment, and in the control group did the routine treatment, then the curative effect, postoperative complications and adverse reactions of the groups were compared. Results The postoperative TIMI class Ⅲ of patients in the observation group were 132 cases, accounting for 91.03%, which was higher than that of control group was 82.07%, the comparative difference was statistically significant. The left heart ejection fraction of theobservation group at 7 days after surgery was 60.44±6.13(%), which was higher than the control group was 52.35±5.89(%), the comparative difference was statistically significant. In the observation group,the patients within 30 days of major adverse cardiac events was 11 cases, the incidence was 4.4%; the patients with major adverse cardiac events in the control group was 25 cases, the incidence was 10%, the incidence of major adverse cardiac events in the control group was significantly higher than the observation group. ConclusionThe tirofibantreatment forthepatients with acute myocardial infarction in PCI can obviously improve the postoperative coronary artery perfusion, improve left ventricular ejection function, reduce the incidence of major adverse cardiac events within 30 days.